- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03803800
Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis (MSCAR)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Limburg
-
Diepenbeek, Limburg, Belgium, 3590
- Hasselt University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Diagnosis Multiple Sclerosis.
- Healthy control.
- Aged >18y.
- Written informed consent.
Exclusion criteria:
- Contraindications to perform moderate to high intensity exercise.
- Participation in another study.
- Experienced acute MS related exacerbation <6 months prior to start of the study
- EDSS score > 6
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Classic training & beta-alanine
Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
|
Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention.
Sessions will include 60min of cycling on a stationary bicycle.
Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
Some subjects will receive the ergogenic supplement beta-alanine.
|
Placebo Comparator: Classic training & placebo
Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
|
Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention.
Sessions will include 60min of cycling on a stationary bicycle.
Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
|
Experimental: Periodized training & beta-alanine
Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
|
Some subjects will receive the ergogenic supplement beta-alanine.
Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
|
Placebo Comparator: Periodized training & placebo
Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
|
Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exercise capacity
Time Frame: 3 weeks
|
Exercise capacity will be assessed using a maximal (12-lead ECG) graded cardiopulmonary exercise test (♂: 30W+15W/min, ♀: 20W+10W/min, GE eBike Basic®) with pulmonary gas exchange analysis (Jaeger Oxycon®).
VO2, VE, RER will be monitored.
This test will be performed at least 48 hours separated from the muscle strength test, to prevent interference of muscle fatigue.
RER values will be evaluated to verify if the test was performed maximally (RER >1.1).
|
3 weeks
|
Serum lactate
Time Frame: 3 weeks
|
During the exercise test, 2min capillary blood samples will be obtained to analyse blood lactate concentrations (Analox®) and determine the anaerobic threshold before, during and after exercise.
|
3 weeks
|
Body composition
Time Frame: 3 weeks
|
hole body fat and lean tissue mass will be obtained using Dual Energy X-ray Absorptiometry scan (DEXA) (Hologic Series Delphi-A Fan Beam X-ray Bone Densitometer, Vilvoorde, Belgium).
|
3 weeks
|
Body mass index
Time Frame: 3 weeks
|
Weight (calibrated analogue weight scale) and height will be combined to report BMI in kg/m^2.
|
3 weeks
|
Strength measurement
Time Frame: 3 weeks
|
Quadriceps and hamstrings muscle strength will be assessed using a isokinetic dynamometer.
Back- and abdominal muscle strength will be assessed using an isokinetic dynamometer (System 3, Biodex, ENRAF-NONIUS, New York, USA).
After adequate warming-up and movement familiarization, subjects will perform 3 maximal isometric contractions of back- and abdominal muscles for 4-5sec.
This test will be executed in two starting positions (semi-flexed and lumbar isolated) to evaluate adequate co-contraction of m.Iliopsoas and m.Glutei during back flexion and extension respectively.
|
3 weeks
|
Muscle carnosine concentration
Time Frame: 3 weeks
|
Muscle biopsies will be obtained from the middle part of the m.vastus lateralis (Bergström needle technique), by an experienced medical doctor.. The first two samples will be immediately embedded in Tissue-Tek, frozen in isopentane cooled with liquid nitrogen and stored at -80°C, until further analysis will be performed. The second two samples will be 'snap freezed' between pincers cooled with liquid nitrogen, and also stored at -80°C until further analysis. Carnosine concentrations will be determined using high-performance liquid chromatography (HPLC). Samples (15mg) are deproteinized using 35% sulfosalicylic acid and centrifuged (5min, 16,000g). Deproteinized supernatant is mixed with AccQ Fluor Borate buffer and reconstituted Fluor Reagent (1:7:2) from the AccQTag chemistry kit (Waters). Derivatized samples are applied to a Waters HPLC system comprised of an AccQTag column (3.9x150mm) and fluorescence detector (excitation/emission wavelength: 250/395nm). |
3 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bert O Eijnde, University Hasselt
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16.111/REVA16.14
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Classic, progressive endurance training
-
University of GiessenHannover Medical SchoolUnknownType 2 DiabetesGermany
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Pulmonary DiseaseGermany
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingParkinson DiseaseUnited States
-
General Committee of Teaching Hospitals and Institutes...Cairo University; Taibah UniversityCompleted
-
University Hospital HeidelbergDietmar Hopp Stiftung; Friederike Rosenberger (University Hospital Heidelberg)...Completed
-
Molde University CollegeCompleted
-
University of ViennaCompletedCOVID-19 | Post-COVID-19 Syndrome | Long COVID-19Austria
-
Landsteiner InstitutLund University; Medical University of Vienna; Mein Hanusch-Krankenhaus; Fondazione... and other collaboratorsCompletedType 2 Diabetes Mellitus | Insulin ResistanceAustria
-
Universität des SaarlandesThe German Heart FoundationCompletedChronic Heart Failure | Dilated CardiomyopathyGermany
-
Hospital Clinic of BarcelonaActive, not recruitingPulmonary Arterial HypertensionSpain